Recipharm Capabilities Update May 2026: Highly Potent Drug Development & Manufacturing

Bringing a high potency product to market is rarely straightforward, especially when timelines slip, API is scarce and processes don't scale as planned.

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) employing over 4,500 employees. Recipharm provides expertise in development and manufacturing across oral dosage, sterile fill & finish and advanced biologics, including high potency products.

This session will show you how to avoid those pitfalls. You'll gain practical insight into how we, at Recipharm, partner with you to reduce API consumption, streamline tech-transfer and shorten timelines while building scalable, reliable processes from day one.